Good find Vinn. Good to see the roll out progressing nicely. MLA set to acquire 60.5% of Medivet US so huge potential here.
from the looks of things the initial arrangement with Butler Schein is non-restrictive which bodes well for full market saturation of the stem cell product.
Looking forward to the next week or two as the announcements start shedding a bit more light on everything.
